Bridging the Innovation Gap: A Strategic Policy Framework for Delaware’s R&D Tax Conformity and Small Business Retroactive Relief

1. The Evolution of R&D Taxation: From Immediate Expensing to the Capitalization Crisis

The state of Delaware stands at a critical juncture in its mission to maintain its status as a global hub for scientific discovery and industrial innovation. For over a century, the First State has leveraged its unique corporate legal infrastructure and favorable tax environment to attract the world’s leading chemical, pharmaceutical, and financial services firms. However, a significant misalignment between federal and state tax policies regarding Research and Development (R&D) expenditures now threatens the liquidity and survival of the state’s burgeoning small and medium-sized business (SMB) sector. The core of this challenge lies in the “Policy Issue” of the amended return deadline: a rapidly closing window for small businesses to claim retroactive relief for previously capitalized R&D expenses from the 2022–2024 era. This window is set to close on July 4, 2026, creating a time-sensitive barrier that could result in the permanent loss of millions of dollars in capital for Delaware-based innovators who remain unaware of the relief mechanism or the state’s current decoupling from federal provisions.

To fully appreciate the gravity of the current policy gap, one must analyze the historical trajectory of Internal Revenue Code (IRC) Section 174. Since 1954, the federal government allowed businesses to immediately deduct 100% of their research and experimental (R&E) expenditures in the year they were incurred.¹ This policy was rooted in the understanding that R&D is inherently risky, often requiring years of “burn” before a viable product reaches the market. By allowing an immediate deduction, the tax code reduced the after-tax cost of innovation and provided essential cash flow to support ongoing experimentation.³

The landscape shifted dramatically with the enactment of the Tax Cuts and Jobs Act (TCJA) of 2017. In a bid to offset corporate rate cuts, the TCJA included a provision—delayed until 2022—that mandated the capitalization and amortization of all R&D expenses.⁵ For the first time in nearly seven decades, companies were forced to spread their domestic R&D deductions over five years and their foreign-sourced R&D deductions over fifteen years.³ This change proved catastrophic for the cash-flow-sensitive SMB sector, particularly in research-intensive fields like biotechnology and software development.

In Delaware, the impact was felt immediately across the “Life Sciences” corridor. Startups that were previously able to offset their R&D spend against other income, or generate net operating losses (NOLs) to carry forward, found themselves facing “phantom profits”.⁹ Because only 10% of their R&D spend was deductible in the first year (due to the mid-year convention), the remaining 90% effectively increased their taxable income, forcing many pre-revenue companies to pay taxes on capital they had already spent on salaries and lab supplies.⁸

2. The One Big Beautiful Bill Act (OBBBA) and the July 4, 2026, Deadline

The federal response to the capitalization crisis arrived with the One Big Beautiful Bill Act (OBBBA), signed on July 4, 2025. This landmark legislation sought to restore the pre-TCJA status quo for domestic innovation by introducing IRC Section 174A, which reinstated the option for immediate expensing of domestic R&D costs for tax years beginning after December 31, 2024.¹ Crucially, the OBBBA included a retroactive “Small Business Relief” provision, allowing firms with average gross receipts of $31 million or less to amend their 2022, 2023, and 2024 returns to claim the full R&D deduction they were previously denied.¹¹

However, this relief comes with a strict “statutory sunset.” The deadline for small businesses to elect this retroactive treatment is July 4, 2026—exactly one year from the bill’s enactment.⁷ For a Delaware business owner, this date represents a hard boundary; failure to act before this deadline results in the permanent forfeiture of the ability to recover capitalized costs from the 2022–2024 period.⁷

Table 1: Evolution of R&D Treatment

3. Delaware’s Regulatory Framework: The Decoupling Challenge

Delaware’s relationship with federal tax law is generally defined by “rolling conformity,” where the state’s tax code automatically adjusts to federal changes. However, following the passage of the OBBBA, the Delaware General Assembly faced a difficult fiscal reality. The Delaware Economic and Financial Advisory Council (DEFAC) projected that immediate and retroactive conformity to the OBBBA could result in a revenue shortfall of approximately $400 million.¹⁸ In response, Governor Matt Meyer signed House Bill 255 on November 19, 2025, effectively “decoupling” Delaware from several key provisions of the OBBBA.¹⁸

Technical Information Memorandum 2025-02

The Delaware Division of Revenue formalized this decoupling through Technical Information Memorandum (TIM) 2025-02. This memorandum clarified that while Delaware would conform to immediate R&D expensing prospectively for tax years starting in 2025, it would specifically reject the federal retroactive treatment for the 2022–2024 period.¹⁸ For Delaware corporate income tax purposes, domestic R&D expenses incurred between 2022 and 2024 must continue to be amortized over five years, even if the federal government allows them to be expensed via an amended return.¹⁸

This decoupling creates a “compliance trap” for Delaware SMBs. A small biotech company in the Delaware Technology Park may successfully amend its federal returns to receive a much-needed cash refund, only to find that its state tax liability remains unchanged, or worse, that it must maintain two entirely different sets of R&D books for the next several years.⁵ This administrative burden is particularly heavy for “pass-through” entities like S-Corporations and Partnerships, which are prevalent in the startup community.¹⁶

4. The Significance of Delaware’s R&D Tax Credit for SMBs

To understand why the capitalization issue is so disruptive, one must view it within the context of the Delaware Research and Development Tax Credit, codified under Title 30, Chapter 20, Subchapter VIII.²³ Delaware’s R&D credit is among the most competitive in the United States, specifically because of its “Small Business Enhancement” and “Full Refundability” features.²³

The 2017 Commitment to Innovation Act

The Delaware R&D credit was historically subject to a $5 million statewide aggregate cap, meaning that if total claims exceeded $5 million, every company’s credit was prorated downward.²³ This made the credit unpredictable and difficult for startups to use in their financial modeling. In 2017, the General Assembly passed the “Commitment to Innovation Act,” which removed the statewide cap and made the credit fully refundable.²³

Table 2: Delaware R&D Tax Credit Parameters

For a Delaware SMB, the “Qualified Research Expenses” (QREs) used to calculate this credit are directly tied to the definition of R&E expenditures under Section 174.³ When the federal government mandated capitalization, it complicated the timing of when these credits could be claimed and the “base amount” calculations required for Method A.¹⁰ The current “Policy Issue” regarding the July 4, 2026, deadline threatens to permanently distort these calculations for the 2022–2024 era, potentially reducing the effective value of the Delaware R&D credit just when startups need it most.

5. Economic Context: The Stakes of Delaware’s Innovation Economy

The urgency of resolving the amended return deadline issue is underscored by Delaware’s heavy economic reliance on R&D-intensive sectors. According to data from the Delaware Prosperity Partnership (DPP), Delaware ranks 6th in the United States for industrial R&D intensity relative to its Gross Domestic Product (GDP).¹⁷ In 2022 alone, over $2 billion was invested in R&D within the state’s borders, accounting for more than 3% of the total state GDP.¹⁷

The Bioscience Sector as a Primary Engine

The bioscience subsector is a particularly potent driver of Delaware’s economy. The “Life Sciences in Delaware: Momentum and Opportunity” report highlights that the sector employs approximately 11,000 people and directly generates $2 billion in GDP.³² Furthermore, the number of biotechnology R&D companies in Delaware has increased by 65% over the last decade.³² These companies often operate on multi-year, pre-revenue cycles where cash is the primary constraint.

The “Incyte and DuPont” Effect

While Delaware is home to giants like Incyte, which spent $2.6 billion on R&D in 2024, and DuPont, which spent $531 million, the health of the ecosystem depends on the “rising stars”.³¹ Small startups often serve as the feeders for these larger firms, and their ability to reinvest every dollar into drug trials or lab equipment is vital. The “phantom profit” generated by R&D capitalization acts as a drain on this ecosystem, diverting capital from the lab to the tax office.⁸

6. Practical Solution 1: Targeted Legislative Recoupling (The “Innovation Continuity Act”)

The first and most robust solution for the Delaware legislature is the enactment of a targeted recoupling bill. This legislation, which could be titled the “Small Business Innovation Continuity Act,” would create a specific carve-out from HB 255 for eligible small businesses.

Mechanism of the Solution

• Partial Recoupling for SMBs: The Act would amend the Delaware Code to adopt the OBBBA’s retroactive treatment of R&D expenses only for businesses meeting the federal $31 million gross receipts threshold.¹¹
• Harmonized Election Window: To address the “Policy Issue” of the closing window, the Act would establish a state-level election period that mirrors the federal July 4, 2026, deadline but allows for a “grace period” of six months to file the state-specific amended returns after the federal amendment has been accepted.
• The “Catch-Up” Election Alternative: To minimize the administrative burden of filing amended returns for three separate years (2022, 2023, 2024), the legislation could allow SMBs to take a single “catch-up” deduction on their 2025 or 2026 state tax return.⁷ This would allow the business to deduct the entire remaining unamortized balance of their 2022–2024 R&D costs in one year, providing an immediate liquidity injection.

Why This Solution Works

By limiting the recoupling to SMBs, the state addresses the $400 million revenue concern that prompted decoupling in the first place.¹⁸ Large corporations, which account for the vast majority of the R&D spend in Delaware, would remain under the five-year amortization schedule for the 2022–2024 period.³¹ For the state, the “cost” of recoupling for SMBs is significantly lower, while the “benefit” to the innovation ecosystem is disproportionately high.

7. Practical Solution 2: Administrative Facilitation and the “R&D Concierge” Program

If the legislature is reluctant to fully recouple due to immediate budget constraints, the Delaware Division of Revenue (DOR) could implement an administrative fix to lower the “time-sensitive barrier” for small businesses.

Mechanism of the Solution

• The “R&D Concierge” Task Force: The DOR could create a dedicated team to assist SMBs in navigating the discrepancies between their federal OBBBA amended returns and their decoupled state returns. This team would provide standardized guidance on how to report the two different sets of R&D books.
• Waiver of Penalties and Interest: The state could issue a standing directive to waive all penalties and interest associated with underpayments resulting from the 2022–2024 R&D capitalization rules, provided the business makes a good-faith effort to reconcile their state returns by a specific date (e.g., December 31, 2026).
• Automatic Extension for Form 2070AC: The current deadline for applying for the Delaware R&D credit is September 15.²³ The DOR could grant an automatic one-year extension for any small business that is in the process of amending its federal returns to reclaim retroactive R&D relief. This ensures that the state credit calculation is based on the finalized, OBBBA-compliant federal figures.

Why This Solution Works

This approach requires no new legislation and does not immediately impact the state’s revenue projections. Instead, it reduces the “administrative friction” that discourages small businesses from claiming the relief they are entitled to federally.³ It also signals that Delaware is “open for business” and supportive of its innovators, even as it manages its fiscal responsibilities.

8. Implementation: Ensuring Integrity and Avoiding Fraud/Wastage

Any policy that provides significant tax relief or refunds is susceptible to exploitation. To protect the Delaware taxpayer and ensure that the benefits reach genuine innovators, the government must implement robust “integrity protocols” alongside any recoupling or administrative relief.

Fraud Prevention via Technical Validation

The primary risk in R&D taxation is the systematic inflation of Qualified Research Expenses (QREs) by “aggressive vendors” who market their services on a contingency-fee basis.³⁵ These vendors may include ineligible costs, such as general administrative wages or routine quality control, in the R&D claim.³

• Mandatory Disclosure of Fee Structures: The Delaware DOR should require any practitioner filing an amended R&D return or a claim for the R&D tax credit to disclose if they are being paid on a contingency basis. This aligns with Circular 230 standards and helps auditors flag potentially high-risk claims.³⁶
• Adoption of the “Four-Part Test” Documentation: The state should mandate that all retroactive R&D claims be accompanied by a “Technical Substantiation Report” that explicitly addresses the federal Four-Part Test: Permitted Purpose, Elimination of Uncertainty, Process of Experimentation, and Technological in Nature.²³
• Randomized Forensic Audits: The DOR should conduct randomized “forensic audits” of retroactive claims, focusing on the “nexus” between the R&D project and the Delaware-based personnel.²⁴ This ensures that the state is not subsidizing research conducted outside its borders.

Strategic Partnerships with Higher Education

Delaware has a unique asset in the University of Delaware (UD), which hosts the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).³² The state government should partner with NIIMBL or UD’s engineering faculty to provide “technical peer review” for highly complex biotech or chemical R&D claims. This ensures that state auditors—who may be experts in tax law but not in biopharmaceutical manufacturing—have access to the technical expertise needed to identify fraudulent or exaggerated claims.³⁵

9. Cost Analysis: Framing the Initial Outlay as a Strategic Investment

Opponents of R&D tax relief often point to the “immediate cost” to the state treasury. However, this is a narrow view that ignores the “multiplier effect” of innovation capital.

The Multiplier Effect of R&D Capital

Research from organizations like the Bipartisan Policy Center suggests that R&D tax incentives have a high return on investment (ROI). For every $1 of tax credit or deduction provided, businesses typically generate more than $1 of additional R&D spending.⁴ In Delaware, this additional spending flows directly into the local economy through:

• High-Wage Payroll Taxes: The average U.S. bioscience worker earns $132,000, which is 83% higher than the private sector average.³⁹ These workers pay significant Delaware personal income tax and payroll withholding.³¹
• Indirect Job Creation: The bioscience industry has a job multiplier of approximately 4.5; for every direct job, an additional 3.5 jobs are supported in the broader economy.³⁹
• Property and Real Estate: R&D labs require specialized facilities, contributing to the state’s commercial real estate tax base and supporting construction jobs.³²

The Cost of “Phantom Profit” Taxation

The cost of not acting is the destruction of the future tax base. When a startup like the “Smyrna-based craft distiller” or a “biotech firm in Dover” is forced to pay taxes on phantom profits, they reduce their “runway”—the amount of time they can survive before needing more venture capital.⁹ If that runway is shortened by even three months, the startup may fail, and the state loses 100% of the future payroll and corporate taxes that the company would have generated over its lifetime.⁸

Table 3: Immediate vs. Deferred Benefits

10. Importance of the Policy Change: The Danger of Inaction

The failure to address the July 4, 2026, deadline and the Delaware decoupling issue will lead to several negative consequences that could haunt the state’s economy for a decade.

1. The “Compliance Gap” Brain Drain: If Delaware remains decoupled while the federal government and neighboring states like Pennsylvania offer catch-up relief, Delaware’s most innovative startups will perceive a “hostile” tax environment.¹⁹ Venture capitalists, who are highly sensitive to tax treatment, may encourage their portfolio companies to move their “principal place of business” across the border to Philadelphia or Maryland to take advantage of more favorable R&D treatments.⁹
2. Bankruptcy of Pre-Revenue Innovators: The “capitalization requirement” of the TCJA era was particularly devastating for companies that rely on federal grants (SBIR/STTR). Because these companies must spend 100% of the grant on research but can only deduct 10% of that spend in the first year, they are left with a massive tax bill and no revenue to pay it.⁸ Without the retroactive relief allowed by the OBBBA, and without state-level support, many of these companies—which are working on cures for Alzheimer’s or Parkinson’s—face bankruptcy.⁸
3. The Permanent Loss of Federal Capital: The July 4, 2026, deadline is a “federal hard stop.” If Delaware businesses are so confused by the state’s decoupling that they miss the federal amendment deadline, they lose millions in federal refunds that would have been reinvested in Delaware labs.⁷ This represents a direct transfer of wealth from Delaware’s innovation economy to the federal treasury, with no corresponding benefit to Delaware’s state budget.
4. Administrative Paralysis: Maintaining two different R&D amortization schedules for a decade (one for federal at 0 years and one for state at 5 years) is an accounting nightmare for an SMB.⁵ This complexity increases the likelihood of errors, which in turn increases the “audit risk” for both the company and the DOR.³⁴ This “friction” discourages companies from applying for the R&D credit altogether, undermining the very purpose of the Delaware R&D tax credit framework.⁴

11. Summary and Recommendations for the Delaware Government

The window for action is narrow. To preserve Delaware’s status as a leader in industrial and academic R&D, the government must move quickly to bridge the gap between state and federal policy. The “Policy Issue” of the closing July 4, 2026, window is a ticking clock for Delaware’s SMBs.

Final Policy Recommendations

• Enact the “Innovation Continuity Act” by June 2026 to allow for a targeted, retroactive “catch-up” deduction for businesses under the $31 million threshold.¹¹
• Launch a Statewide Awareness Campaign in partnership with the Delaware BioScience Association and the Delaware State Chamber of Commerce to ensure every small business is aware of the July 4, 2026, federal amendment deadline.⁷
• Direct the Division of Revenue to prioritize the processing of Form 2070AC for small businesses, ensuring that “fully refundable” credits are paid out as quickly as possible to provide the liquidity needed to offset the 2022–2024 capitalization burden.²³
• Strengthen Audit Integrity by mandating contingency-fee disclosures and leveraging the technical expertise of the University of Delaware to prevent “wastage” in the R&D credit program.³⁵

By taking these steps, Delaware can ensure that its tax code remains a catalyst for innovation rather than a barrier. The initial revenue deferral required to support our small businesses will be repaid many times over through the growth of high-wage jobs, the expansion of the life sciences sector, and the preservation of Delaware’s unique competitive edge in the global innovation economy.

Obras citadas

1. What will be the impact of Section 174 in 2026? – Thomson Reuters Institute, acceso: marzo 17, 2026, https://www.thomsonreuters.com/en-us/posts/corporates/section-174-future/
2. State Conformity to Section 174 – Credit Fund Advisors LLC, acceso: marzo 17, 2026, https://www.creditfundadvisors.com/blog/state-conformity-to-irc-section-174
3. Section 174: Understanding Research & Development expenditures – Thomson Reuters, acceso: marzo 17, 2026, https://www.thomsonreuters.com/en-us/posts/tax-and-accounting/section-174-expenditures/
4. Bad breaks: Why US tax policies put innovation at risk, acceso: marzo 17, 2026, https://siepr.stanford.edu/publications/policy-brief/bad-breaks-why-us-tax-policies-put-innovation-risk
5. Treatment of Domestic R&E Expenditures under the One Big Beautiful Bill Act—State Tax and Important Federal Considerations – KPMG, acceso: marzo 17, 2026, https://kpmg.com/kpmg-us/content/dam/kpmg/taxnewsflash/pdf/2026/01/010726-S174A-RD-State.pdf
6. IRS Updated R&E Expensing | Retroactive Deductions | Delaware …, acceso: marzo 17, 2026, https://www.belfint.com/changes-to-r-and-e-expensing/
7. Skipped R&D Tax Credits in 2022–2024? How to Recover Missed Refunds Before 2026 | StrikeTax.com, acceso: marzo 17, 2026, https://www.striketax.com/journal/did-you-skip-r-d-tax-credits-in-2022-2024
8. Why R&D Tax Changes Are Hurting America’s Biotech Industry – Biocom, acceso: marzo 17, 2026, https://www.biocom.org/policy-advocacy/rdamortization/
9. Biotech R&D Credits: The New OBBBA Rules You Should Know in 2025, acceso: marzo 17, 2026, https://alternatetaxsolutions.com/biotech-obbba-rd-tax-credits-2025/
10. R&D Tax Credit Capitalization: Definition, Benefits and Proposed Changes – Cherry Bekaert, acceso: marzo 17, 2026, https://www.cbh.com/insights/articles/rd-capitalization-tax-reform-explained/
11. The R&D Tax Credit in 2026: Key Changes to Be Aware Of – CSSI Services, acceso: marzo 17, 2026, https://cssiservices.com/rd-tax-credit-in-2026/
12. Filing Deadline 2026: Key R&D Tax Credit Dates – Leyton, acceso: marzo 17, 2026, https://leyton.com/us/insights/articles/filling-deadline-2026-key-rd-tax-credit-dates/
13. Retroactive Reversal of Sec. 174 Amortization: July 6 Deadline Approaches, acceso: marzo 17, 2026, https://capstantax.com/retroactive-reversal-of-sec-174-amortization-july-6-deadline-approaches/
14. Section 174 Fixed: What Businesses Need to Know About R&E Expensing Changes – KLR, acceso: marzo 17, 2026, https://kahnlitwin.com/blogs/tax-blog/section-174-fixed-what-businesses-need-to-know-about-r-e-expensing-changes
15. Latest Updates on Section 174: Congress Acts on R&D Tax Law Changes – 2026 Tax News – ABGi USA, acceso: marzo 17, 2026, https://abgi-usa.com/section174/latest-and-greatest
16. Section 174: Tips, Traps, & Taxpayer Guidance | Forvis Mazars US, acceso: marzo 17, 2026, https://www.forvismazars.us/forsights/2026/02/section-174-tips-traps-taxpayer-guidance
17. R&D Benefits for DE Innovators Restored | DPP – Delaware Prosperity Partnership, acceso: marzo 17, 2026, https://www.choosedelaware.com/in-the-news/rd-benefits-for-de-innovators-restored/
18. Division of Revenue Technical Information Memorandum 2025-02 – Delaware.gov, acceso: marzo 17, 2026, https://revenuefiles.delaware.gov/2025/TIMs/HB_255_TIM.pdf
19. Some States Are Splitting from the OBBB – Is Yours?, acceso: marzo 17, 2026, https://www.horty.com/2025/12/19/some-states-are-splitting-from-the-obbb-is-yours/
20. PA, Delaware Partially Decouple from Key OBBBA Rules | Grant …, acceso: marzo 17, 2026, https://www.grantthornton.com/insights/alerts/tax/2025/salt/p-t/pa-delaware-decouple-key-obbba-rules-12-23
21. State corporate income tax law changes for the fourth quarter of 2025 | RSM US, acceso: marzo 17, 2026, https://rsmus.com/insights/tax-alerts/2026/state-corporate-income-tax-law-changes.html
22. The Patchwork of State Conformity to the OBBBA | Crowe LLP, acceso: marzo 17, 2026, https://www.crowe.com/insights/tax-news-highlights/the-patchwork-of-state-conformity-to-the-obbba
23. Research and Development (R&D) Tax Credits for Dover, Delaware Businesses – Swanson Reed, acceso: marzo 17, 2026, https://www.swansonreed.com/research-tax-credit/delaware/case-studies/dover/
24. Delaware R&D Tax Credits – Strike Tax Advisory, acceso: marzo 17, 2026, https://www.striketax.com/state-rd-credits/delaware-r-d-tax-credits
25. OBBBA R&D Expensing Changes: Amend Returns or Take 2025–2026 Deductions, acceso: marzo 17, 2026, https://www.specialtytaxgroup.com/obbba-changes-to-r-and-d-expensing-amending-tax-returns-under-the-small-business-rules
26. 30 Delaware Code § 2070 (2025) – Amount of credit and applicable procedures., acceso: marzo 17, 2026, https://law.justia.com/codes/delaware/title-30/chapter-20/subchapter-viii/section-2070/
27. Research and Development (R&D) Tax Credits for Smyrna, Delaware Businesses – Swanson Reed, acceso: marzo 17, 2026, https://www.swansonreed.com/research-tax-credit/delaware/case-studies/smyrna/
28. Are R&D Tax Credits Available in Delaware? | See if You Qualify – KBKG, acceso: marzo 17, 2026, https://www.kbkg.com/research-tax-credit/delaware-rd-tax-credit
29. FORM 2071AC 0007 – State of Delaware, acceso: marzo 17, 2026, https://revenuefiles.delaware.gov/docs/2071ACe.pdf
30. ACCELERATING DELAWARE’S LIFE SCIENCE LEADERSHIP, acceso: marzo 17, 2026, https://cdn.ymaws.com/www.delawarebio.org/resource/resmgr/custom_pages/policy_report/State_Advocacy_for_Life_Scie.pdf
31. Delaware hopes to see gains with the return of R&D expensing …, acceso: marzo 17, 2026, https://www.delawarebio.org/news/709599/Delaware-hopes-to-see-gains-with-the-return-of-RD-expensing.htm
32. Life Sciences in Delaware Momentum and Opportunity, acceso: marzo 17, 2026, https://www.delawarebio.org/page/Life-Sciences-Delaware-Momentum-Opportunity
33. Major tax wins for startups: R&D relief and hiring credits explained – NextCorps, acceso: marzo 17, 2026, https://nextcorps.org/major-tax-wins-for-startups-rd-relief-and-hiring-credits-explained/
34. R&D Tax Credit | Advisory and Audit Services – Anchin, acceso: marzo 17, 2026, https://www.anchin.com/services/research-development-tax-credits/rd-audit-defense/
35. Research Credit Claims Audit Techniques Guide (RCCATG): Credit for increasing research activities Section 41* | Internal Revenue Service, acceso: marzo 17, 2026, https://www.irs.gov/businesses/research-credit-claims-audit-techniques-guide-rccatg-credit-for-increasing-research-activities-section-41
36. Common R&D tax credit scams to avoid, acceso: marzo 17, 2026, https://www.swansonreed.com/research-tax-credit/federal/faqs/common-rd-tax-credit-scams-to-avoid/
37. Research & Development Tax Credit Audit Defense – R&D Tax Savers, acceso: marzo 17, 2026, https://www.rdtaxsavers.com/AuditDefense
38. Economic Impact Studies | Institutional Research and Effectiveness – University of Delaware, acceso: marzo 17, 2026, https://ire.udel.edu/ir/financial-data/economic-impact-studies/
39. The U.S. Bioscience Industry: – Biotechnology Innovation Organization | BIO, acceso: marzo 17, 2026, https://www.bio.org/sites/default/files/2025-12/BIO%20CSBA_2025%20Best%20Practices%20Report.pdf
40. R&D Tax Credits in Delaware – GOAT Tax, acceso: marzo 17, 2026, https://www.goat.tax/state-details/r-d-tax-credits-delaware